Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C30H44O3 |
Molecular Weight | 452.6686 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@H](OC(=O)CCCCCCCCC=C)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CCC4=CC(=O)C=C[C@]34C
InChI
InChIKey=AHMMSNQYOPMLSX-CNQKSJKFSA-N
InChI=1S/C30H44O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h4,17,19,21,24-27H,1,5-16,18,20H2,2-3H3/t24-,25-,26-,27-,29-,30-/m0/s1
Molecular Formula | C30H44O3 |
Molecular Weight | 452.6686 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugs.com/vet/equipoise.html
Sources: https://www.drugs.com/vet/equipoise.html
Boldenone (INN, BAN), also known as Δ1-testosterone, 1-dihydrotestosterone, or androsta-1,4-dien-3-one-17β-ol (train name Equipoise) is a long-acting injectable anabolic agent for horses, supplied in a vial providing 50 mg boldenone undecylenate per mL in sesame oil with 3% (w/v) benzyl alcohol as a preservative. The activity of boldenone is mainly anabolic, with a low androgenic potency. Boldenone will increase nitrogen retention, protein synthesis increases appetite and stimulates the release of erythropoietin in the kidneys. Boldenone was synthesized in an attempt to create a long-acting injectable methandrostenolone (Dianabol), for androgen deficiency disorders. Boldenone acts similar to methandrostenolone with fewer adverse androgenic effects. Although commonly compared to nandrolone, boldenone lacks progesterone receptor interaction and all the associated progestogenic side effects. Equipoise (Boldenone Undecylenate Injection) is recommended as an aid for treating debilitated horses when an improvement in weight, haircoat or general physical condition is desired. Debilitation often follows disease or may occur following overwork and overexertion. Boldenone improves the general state of debilitated horses, thus aiding in correcting weight losses and improving appetite. It is not a substitute for a well-balanced diet. Optimal results can be expected only when good management and feeding practices are utilized. Boldenone should be considered only as adjunctive therapy to other specific and supportive therapy for diseases, surgical cases, and traumatic injuries.
CNS Activity
Originator
Sources: https://www.google.com/patents/US2962422
Curator's Comment: # Pfizer & Co C
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11252818 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Equipoise Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Functional analysis and androgen-regulated expression of mouse organic anion transporting polypeptide 1 (Oatp1) in the kidney. | 2001 Mar 19 |
|
Inhibitors of 5alpha -reductase type I in LNCaP cells from the roots of Angelica koreana. | 2002 Feb |
|
An assessment of in vitro androgenic activity and the identification of environmental androgens in United Kingdom estuaries. | 2002 Jul |
|
Confirmatory analysis of 17beta-boldenone, 17alpha-boldenone and androsta-1,4-diene-3,17-dione in bovine urine by liquid chromatography-tandem mass spectrometry. | 2003 Jun 15 |
|
Dihydrotestesterone induction of EPHB2 expression in the female genital tubercle mimics male pattern of expression during embryogenesis. | 2003 Oct |
|
Interactions of androgens, green tea catechins and the antiandrogen flutamide with the external glucose-binding site of the human erythrocyte glucose transporter GLUT1. | 2003 Oct |
|
Evidence for false-positive results for boldenone testing of veal urine due to faecal cross-contamination during sampling. | 2004 Aug |
|
Histopathological effects of boldenone in cattle. | 2004 Mar |
|
Detection of endogenous boldenone in the entire male horses. | 2004 Sep 5 |
|
The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells. | 2005 |
|
Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. | 2005 May |
|
A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. | 2005 May |
|
Rapid test by liquid chromatography/tandem mass spectrometry to evaluate equine urine reactivity towards 17beta-OH steroids. | 2006 |
|
Characterization of boldione and its metabolites in human urine by liquid chromatography/electrospray ionization mass spectrometry and gas chromatography/mass spectrometry. | 2006 |
|
17beta-hydroxy-5alpha-androst-1-en-3-one (1-testosterone) is a potent androgen with anabolic properties. | 2006 Aug 20 |
|
Criteria to distinguish between natural situations and illegal use of boldenone, boldenone esters and boldione in cattle 1. Metabolite profiles of boldenone, boldenone esters and boldione in cattle urine. | 2006 Dec |
|
Neoformation of boldenone and related steroids in faeces of veal calves. | 2006 Feb |
|
Alteration of gene expression in response to bone morphogenetic protein-2 in androgen-dependent human prostate cancer LNCaP cells. | 2006 Feb |
|
Dehydroepiandrosterone decreases while cortisol increases in vitro growth and viability of Entamoeba histolytica. | 2006 Feb |
|
Multi residue screening of intact testosterone esters and boldenone undecylenate in bovine hair using liquid chromatography electrospray tandem mass spectrometry. | 2006 Jan 2 |
|
Winter profile of plasma sex steroid levels in free-living male western diamond-backed rattlesnakes, Crotalus atrox (Serpentes: Viperidae). | 2006 Oct |
|
Screening of boldenone and methylboldenone in bovine urine using disposable electrochemical immunosensors. | 2006 Sep |
|
Pharmacokinetics of boldenone and stanozolol and the results of quantification of anabolic and androgenic steroids in race horses and nonrace horses. | 2007 Apr |
|
Excretion profile of boldenone and its metabolites after oral administration to veal calves. | 2007 Apr 25 |
|
Development of an immunosensor for the detection of testosterone in bovine urine. | 2007 Jan 30 |
|
Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors. | 2007 Jun 1 |
|
Survey of nutritional supplements for selected illegal anabolic steroids and ephedrine using LC-MS/MS and GC-MS methods, respectively. | 2007 Mar |
|
An in vitro study on metabolism of 17beta-boldenone and boldione using cattle liver and kidney subcellular fractions. | 2007 Mar 14 |
|
Phytosterols and anabolic agents versus designer drugs. | 2007 Mar 14 |
|
The ultimate veal calf reference experiment: hormone residue analysis data obtained by gas and liquid chromatography tandem mass spectrometry. | 2007 Mar 14 |
|
Pathology of the testicle and sex accessory glands following the administration of boldenone and boldione as growth promoters in veal calves. | 2007 Nov |
|
Fractionation of free and conjugated steroids for the detection of boldenone metabolites in calf urine with ultra-performance liquid chromatography/tandem mass spectrometry. | 2008 Aug |
|
Mitochondrial redox signaling by p66Shc is involved in regulating androgenic growth stimulation of human prostate cancer cells. | 2008 Aug 28 |
|
Cytogenetic and clinical studies of a male infant with disorder of sexual development: case report. | 2008 Nov |
|
The development of multiple drug use among anabolic-androgenic steroid users: six subjective case reports. | 2008 Nov 28 |
|
Validation and application of a yeast bioassay for screening androgenic activity in calf urine and feed. | 2009 Apr 1 |
|
Metabolism of androsta-1,4,6-triene-3,17-dione and detection by gas chromatography/mass spectrometry in doping control. | 2009 Jan |
|
The risk of hepatotoxicity during long-term and low-dose flutamide treatment in hirsutism. | 2009 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/vet/equipoise.html
The dosage for horses is 0.5 mg per pound of body weight intramuscularly. Treatment may be repeated at three week intervals.
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11252818
The rhAR preparation was diluted 150 in assay buffer (5 mM Na2HP04, 150 mM NaCl, pH 7.2, containing 0.16% w/v protease inhibitor mix and 0.1% bovine serum albumin). Aliquots of 0.5 mL were incubated at 04°C for 16 hours with a constant amount of 0.4 nM 3H-DHT and in the presence or absence of increasing concentrations of Boldenone . DHT was used in all experiments as standard. To separate bound and free ligand, the receptor preparation was incubated with 100 mkL of dextrancoated charcoal (4%) charcoal and 0.4% dextran in assay buffer) for 5 min before centrifugation at 2000 x g for 15 min at 4°C. 0.4 mL of the supernatant was transferred into scintillation vials, mixed with 3 mL Xylofluor and counted. Specific binding represents the relative difference of total binding and non specific binding observed in the presence of a 250 fold surplus of unlabelled DHT.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:33:29 UTC 2023
by
admin
on
Fri Dec 15 15:33:29 UTC 2023
|
Record UNII |
ZS6D2ITA30
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2360
Created by
admin on Fri Dec 15 15:33:29 UTC 2023 , Edited by admin on Fri Dec 15 15:33:29 UTC 2023
|
||
|
DEA NO. |
4000
Created by
admin on Fri Dec 15 15:33:29 UTC 2023 , Edited by admin on Fri Dec 15 15:33:29 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m2597
Created by
admin on Fri Dec 15 15:33:29 UTC 2023 , Edited by admin on Fri Dec 15 15:33:29 UTC 2023
|
PRIMARY | Merck Index | ||
|
SUB125939
Created by
admin on Fri Dec 15 15:33:29 UTC 2023 , Edited by admin on Fri Dec 15 15:33:29 UTC 2023
|
PRIMARY | |||
|
DB14639
Created by
admin on Fri Dec 15 15:33:29 UTC 2023 , Edited by admin on Fri Dec 15 15:33:29 UTC 2023
|
PRIMARY | |||
|
13103-34-9
Created by
admin on Fri Dec 15 15:33:29 UTC 2023 , Edited by admin on Fri Dec 15 15:33:29 UTC 2023
|
PRIMARY | |||
|
CHEMBL2106059
Created by
admin on Fri Dec 15 15:33:29 UTC 2023 , Edited by admin on Fri Dec 15 15:33:29 UTC 2023
|
PRIMARY | |||
|
Boldenone undecylenate
Created by
admin on Fri Dec 15 15:33:29 UTC 2023 , Edited by admin on Fri Dec 15 15:33:29 UTC 2023
|
PRIMARY | |||
|
236-024-5
Created by
admin on Fri Dec 15 15:33:29 UTC 2023 , Edited by admin on Fri Dec 15 15:33:29 UTC 2023
|
PRIMARY | |||
|
DTXSID00156854
Created by
admin on Fri Dec 15 15:33:29 UTC 2023 , Edited by admin on Fri Dec 15 15:33:29 UTC 2023
|
PRIMARY | |||
|
100000151640
Created by
admin on Fri Dec 15 15:33:29 UTC 2023 , Edited by admin on Fri Dec 15 15:33:29 UTC 2023
|
PRIMARY | |||
|
C83559
Created by
admin on Fri Dec 15 15:33:29 UTC 2023 , Edited by admin on Fri Dec 15 15:33:29 UTC 2023
|
PRIMARY | |||
|
2289409
Created by
admin on Fri Dec 15 15:33:29 UTC 2023 , Edited by admin on Fri Dec 15 15:33:29 UTC 2023
|
PRIMARY | |||
|
11954310
Created by
admin on Fri Dec 15 15:33:29 UTC 2023 , Edited by admin on Fri Dec 15 15:33:29 UTC 2023
|
PRIMARY | |||
|
ZS6D2ITA30
Created by
admin on Fri Dec 15 15:33:29 UTC 2023 , Edited by admin on Fri Dec 15 15:33:29 UTC 2023
|
PRIMARY | |||
|
C001371
Created by
admin on Fri Dec 15 15:33:29 UTC 2023 , Edited by admin on Fri Dec 15 15:33:29 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |